Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENELUX CorpGNLX · Entity 1116 | Chief Medical Officer | October 18, 2024 | October 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENELUX Corp
Report date October 18, 2024 · Filed October 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2034-10-17 | Direct | 16,666 |
Reported balance
After 2024-10-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-18 · Grant · Acquired 16,666 · Balance 16,666 F1: Immediately exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2034-10-17 | Direct | 16,666 |
Reported balance
After 2024-10-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-10-18 · Grant · Acquired 16,666 · Balance 16,666 F2: 100% of the shares subject to the Option shall vest on December 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately exercisable.
F2: 100% of the shares subject to the Option shall vest on December 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2024 Filed Oct 21, 2024 21:05 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (right to buy) · Derivative | 16,666 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025460 · form4-10212024_051002.xml · derivative · entry 2 Scigalla Paul · CIK 0001937586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2034-10-17 F2 · derivative.exercise_date: 100% of the shares subject to the Option shall vest on December 31, 2024. Read SEC document |
| October 18, 2024 Filed Oct 21, 2024 21:05 UTC | GENELUX Corp GNLX · Entity 1116 | GrantStock Option (right to buy) · Derivative | 16,666 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025460 · form4-10212024_051002.xml · derivative · entry 1 Scigalla Paul · CIK 0001937586 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2034-10-17 F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.